BioNTech, COVID-19 vaccine
BioNTech plots first wave of cancer launches in 2026 as COVID vaccine sales continue to disappoint
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. | With plans to have at least 10 potentially registrational trials underway by the end of 2024,
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
BioNTech stock seesawed before closing in the green on Monday following a disappointing first-quarter showing.Please watch the video at Investors.com - Biotech Stocks Are Shooting Higher. Here's How You Can Play Them.
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines declined.
BioNTech records Q1 net loss, revenue falls on lower COVID vaccine sales
Additionally, BioNTech’s diluted earnings per share dropped from €2.05 in Q1 2023 to a net loss per share of €1.31. Beyond the topline results, BioNTech’s quarterly R&D expenses totaled €507.5 million, up from €334 million in Q1 2023, while its general and administrative expenses increased from €111.8 million to €117 million.
BioNTech Swings to Net Loss on Lower Covid Vaccine Sales
By Helena Smolak BioNTech swung to a net loss in the first quarter on plummeted revenue after a sharp decline in its Covid-19 vaccine sales. The
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline
BioNTech (BNTX) on Monday swung to a first-quarter loss as the German drugmaker's revenue tumbled more than expected year-on-year due to lower commercial sales of its COVID-19 vaccine. The company posted a per-share loss of 1.
bovnews6h
What’s best: jumping in or staying out? BioNTech SE ADR (BNTX) Stock
BMO Capital Markets raised the price target for the BioNTech SE ADR (NASDAQ:BNTX) stock to “an Outperform”. The rating was released on February 23, 2024, according to finviz. The research report from ...
BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday ...
BioNTech: Undecided Between A One Trick Pony And A Full-Fledged Pharma Company
BioNTech is a biotech company with a strong cash position and a commercial program generating cash-flow. Explore more details ...
BioSpace4d
BioNTech Misses Q1 Earnings, Revenue on Lower COVID-19 Sales
Reeling from “endemic-level demand” for its COVID-19 vaccine, BioNTech on Monday reported a steep decline in revenues and a ...
Benzinga.com on MSN4d
What's Going With BioNTech Stock On Monday?
BioNTech said it is still targeting 2024 revenues of 2.5 billion euros to 3.1 billion euros. Loading... Loading... Monday, ...
Yahoo Finance3d
BioNTech reports net loss of €315.1m in Q1 2024
BioNTech has experienced a significant shift in its financial standing, reporting a net loss of €315.1m ($339.3m) in the ...
Business Insider4d
BioNTech: Hold Rating Maintained Amidst Lower Q1 Earnings and Steady Revenue Outlook
Chris Shibutani has given his Hold rating due to a combination of factors including BioNTech SE’s recent financial performance and future prospects. The company’s first-quarter earnings for 2024 ...
Hosted on MSN2d
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday. Shares of BioNTech SE ...